Compare Eli Lilly And Co (LLY) vs United Airlines Holdings Inc (UAL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

United Airlines (UAL) trades at $116.77, up 1.18% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 10.81 and consistent earnings beats, including Q2 2026 EPS of $1.99 versus $1.88 expected. Revenue growth is robust, rising to $59.07B in 2025, though fuel costs pose headwinds. Analyst consensus is strongly bullish with a $163.75 price target and no sell ratings among 47 analysts.

Outlook remains positive due to resilient travel demand and premium revenue growth, but investors face risks from volatile fuel prices and operational disruptions. The stock offers value with low valuation multiples and upward earnings revisions, yet macroeconomic sensitivity requires caution.